Synergistic antibiotic activity against planktonic and biofilmembedded Streptococcus agalactiae, Streptococcus pyogenes and Streptococcus oralis

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 11, 2017, Pages 3085-3092

  Moreno, Mercedes Gonzalez ^a   Trampuz, Andrej ^a   Di Luca, Mariagrazia ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; PENICILLIN G; PROTEINASE K; RIFAMPICIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BIOFILM; DEVICE INFECTION; DRUG POTENTIATION; EPSILOMETER TEST; IN VITRO STUDY; MICROCALORIMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS ORALIS; STREPTOCOCCUS PYOGENES; CALORIMETRY; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY; STREPTOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BIOFILMS; CALORIMETRY; DAPTOMYCIN; FOSFOMYCIN; GENTAMICINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PLANKTON; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS ORALIS; STREPTOCOCCUS PYOGENES;

EID: 85032227926     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx265     Document Type: Article

References (35)

1. Vinh DC, Embil JM. Device-related infections: a review. J Long TermEffMed Implants 2005; 15: 467-88
2. Trampuz A, Zimmerli W. Prosthetic joint infections: update in diagnosis and treatment. SwissMed Wkly 2005; 135: 243-51
3. Farley MM, Strasbaugh LJ. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis 2001; 33: 556-61
4. Darenberg J, Henriques-Normark B, Lepp T et al. Increased incidence of invasive group A streptococcal infections in Sweden, January 2012-February 2013. Euro Surveill 2013; 18: pii'20443
5. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 2001; 33: S94-106
6. Zeller V, Lavigne M, Leclerc P et al. Group B streptococcal prosthetic joint infections: a retrospective study of 30 cases. Presse Méd 2009; 38: 1577-84
7. Everts RJ, Chambers ST, Murdoch DR et al. Successful antimicrobial therapy and implant retention for streptococcal infection of prosthetic joints. ANZ J Surg 2004; 74: 210-4
8. Peel T, Buising K, Dowsey M et al. Management of prosthetic infection according to organism, arthroplasty. https://www. intechopen. com/books/ arthroplasty-update/management-of-prosthetic-infection-according-toorganism
9. Traub WH, Leonhard B. Antibiotic susceptibility of alpha-and nonhemolytic streptococci from patients and healthy adults to 24 antimicrobial drugs. Chemotherapy 1997; 43: 123-31
10. Maduri-Traczewski M, Szymczak EG, Goldmann DA. In vitro activity of penicillin and rifampin against group B streptococci. Rev Infect Dis 1983; 5 Suppl 3: S586-92
11. von Ah U, Wirz D, Daniels AU. Isothermal micro calorimetry-a new method for MIC determinations: results for 12 antibiotics and reference strains of E. coli and S. aureus. BMCMicrobiol 2009; 9: 106
12. Di Luca M, Navari E, Esin S et al. Detection of biofilms in biopsies from chronic rhinosinusitis patients: in vitro biofilm forming ability and antimicrobial susceptibility testing in biofilm mode of growth of isolated bacteria. Adv ExpMed Biol 2017; doi:10. 1007/5584_2017_34
13. Oliva A, Furustrand Tafin U, Maiolo EM et al. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model. Antimicrob Agents Chemother 2014; 58: 1284-93
14. Trampuz A, Piper KE, Jacobson MJ et al. Sonication of removed hip and knee prostheses for diagnosis of infection. NEngl JMed2007; 357: 654-63
15. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. JAntimicrobChemother 2003; 52: 1
16. Doern CD, Roberts AL, Hong W et al. Biofilm formation by group A Streptococcus: a role for the streptococcal regulator of virulence (Srv) and streptococcal cysteine protease (SpeB). Microbiology 2009; 155: 46-52
17. The European Committee on Antimicrobial Susceptibility Testing-EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 7. 1, 2017. European Society of Clinical Microbiology and Infectious Diseases. http://www. eucast. org/fileadmin/src/media/PDFs/EUCAST_files/ Breakpoint_tables/v_7. 1_Breakpoint_Tables. pdf
18. Streit JM, Steenbergen JN, Thorne GM et al. Daptomycin tested against 915. bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. JAntimicrobChemother 2005; 55: 574-8
19. Smith A, Jackson MS, Kennedy H. Antimicrobial susceptibility of viridans group streptococcal blood isolates to eight antimicrobial agents. Scand J Infect Dis 2004; 36: 259-63
20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 27th Edition. CLSIM100-S27. CLSI, Wayne, PA, USA, 2016
21. Maraki S, Samonis G, Rafailidis PI et al. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009; 53: 4508-10
22. de Cueto M, Lopez L, Hernandez JR et al. In vitro activity of fosfomycin against extended-spectrum-b-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006; 50: 368-70
23. Ruppen C, Hemphill A, Sendi P. In vitro activity of gentamicin as an adjunct to penicillin against biofilm group B Streptococcus. J Antimicrob Chemother 2017; 72: 444-7
24. Lauderdale KJ, Malone CL, Boles BR et al. Biofilm dispersal of communityassociatedmethicillin-resistant Staphylococcus aureus on orthopedic implant material. JOrthopRes 2010; 28: 55-61
25. Kaplan JB, LoVetri K, Cardona ST et al. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo) 2012; 65: 73-7
26. Kumar Shukla S, Rao TS. Dispersal of Bap-mediated Staphylococcus aureus biofilm by proteinase K. JAntibiot (Tokyo) 2013; 66: 55-60
27. Sendi P, Christensson B, Uckay I et al. Group B streptococcus in prosthetic hip and knee joint-associated infections. J Hosp Infect 2011; 79: 64-9
28. Fiaux E, TitecatM, RobineauO et al. Outcome of patientswith streptococcal prosthetic joint infections with special reference to rifampicin combinations. BMC Infect Dis 2016; 16: 568
29. Akgun D, Trampuz A, Perka C et al. High failure rates in treatment of streptococcal periprosthetic joint infection: results from a seven-year retrospective cohort study. Bone Joint J 2017; 99-B: 653-9
30. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 2011; 473: 216-20
31. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-54
32. Norden CW. Experimental osteomyelitis. IV. Therapeutic trialswith rifampin alone and in combination with gentamicin, sisomicin, and cephalothin. J Infect Dis 1975; 132: 493-9
33. Lowy FD, Chang DS, Lash PR. Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci. Antimicrob Agents Chemother 1983; 23: 932-4
34. Moellering RC Jr, Wennersten C, Weinberg AN. Synergy of penicillin and gentamicin against enterococci. J Infect Dis 1971; 124 Suppl: S207-9
35. Miller MH, el-Sokkary MA, Feinstein SA et al. Penicillin-induced effects on streptomycin uptake and early bactericidal activity differ in viridans group and enterococcal streptococci. Antimicrob Agents Chemother 1986; 30: 763-8